US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Thursday that it has entered into a strategic research collaboration with Isomorphic Labs, an AI-first drug design and development company, to discover small-molecule therapeutic candidates targeting an oncology indication.
The collaboration combines Isomorphic Labs' AI-driven drug design capabilities with Merck's proprietary data and drug discovery expertise.
Under the agreement, Isomorphic Labs will conduct computational predictions and deliver molecular designs using its proprietary drug design engine, IsoDDE, incorporating selected data sets provided by Merck. Merck will oversee preclinical and clinical development, manufacturing and commercialisation of any resulting products.
Isomorphic Labs will receive an upfront payment and be eligible for research, development, regulatory and commercial milestone payments, alongside tiered royalties on net sales. The agreement also grants Isomorphic Labs an option to co-fund development activities in exchange for higher royalty rates.
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Apotex launches generic version of INLYTA in US market
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism